Efficacy Of Sr-89 To Painful Bone Metastases For Japanese Breast Cancer Patients.

e12063 Background: Bone modifying agents, zoledronic acid or Denosumab are first choice for bone metastases as standard therapy. However some patients are still painful. The purpose of this study was to examine the safety and efficacy of the concurrent use of the radiopharmaceutical strontium-89 (Sr-89) chloride with zoledronic acid in standard anticancer therapy for breast cancer patients with painful multifocal bone metastases. Methods: The subjects were 42 breast cancer Japanese women with painful bone metastases detected by bone scintigraphy, computed tomography or magnetic resonance imaging, in whom Sr-89 was added to zoledronic acid continuous therapy, or was added after an initial administration of zoledronic acid at the Department of Radiology in our hospital, between October 2007 and December 2014. Results: The median age of the subjects was 56 y-o (39–77 y-o).The average period of using zoledronic acid before Sr-89 administration is 15.8 months (0-64months). In this study, the median survival pe...